A Novel C5a-neutralizing Mirror-image (l-)Aptamer Prevents Organ Failure and Improves Survival in Experimental Sepsis
暂无分享,去创建一个
Markus Huber-Lang | S. Klußmann | M. Huber-Lang | K. Buchner | C. Maasch | A. Vater | W. Purschke | Werner G Purschke | Klaus Buchner | Christian Maasch | Axel Vater | Sven Klussmann | Kai Hoehlig | Nelli Shushakova | K. Hoehlig | N. Shushakova | Kai Hoehlig
[1] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[2] L. Birnbaumer,et al. Macrophages Induce the Inflammatory Response in the Pulmonary Arthus Reaction through Gαi2 Activation That Controls C5aR and Fc Receptor Cooperation1 , 2005, The Journal of Immunology.
[3] Ronny Lorenz,et al. The Vienna RNA Websuite , 2008, Nucleic Acids Res..
[4] A. Blom,et al. Early Complementopathy After Multiple Injuries in Humans , 2012, Shock.
[5] R A Bendele,et al. Derivation of RNA aptamer inhibitors of human complement C5. , 1999, Immunopharmacology.
[6] J. V. D. van der Meer,et al. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. , 2003, Blood.
[7] John D Lambris,et al. Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.
[8] C. Mackay,et al. Functional roles for C5a receptors in sepsis , 2008, Nature Medicine.
[9] N. Janjić,et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.
[10] C. Gerard,et al. The chemotactic receptor for human C5a anaphylatoxin , 1991, Nature.
[11] S. Klußmann,et al. Targeting complement component 5a promotes vascular integrity and limits airway remodeling , 2013, Proceedings of the National Academy of Sciences.
[12] V. Erdmann,et al. Mirror-image RNA that binds D-adenosine , 1996, Nature Biotechnology.
[13] A. Schmaier,et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. , 2002, The American journal of pathology.
[14] T. van der Poll,et al. Peritoneal macrophages are important for the early containment of Enterococcus faecium peritonitis in mice , 2009, Innate immunity.
[15] P. Ward,et al. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. , 2012, Advances in experimental medicine and biology.
[16] S. Klußmann,et al. Polyetheylenimine-Polyplexes of Spiegelmer NOX-A50 Directed against Intracellular High Mobility Group Protein A1 (HMGA1) Reduce Tumor Growth in Vivo* , 2010, The Journal of Biological Chemistry.
[17] P. Monk,et al. The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg74 * , 2002, The Journal of Biological Chemistry.
[18] John D Lambris,et al. Protection of innate immunity by C5aR antagonist in septic mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] D. Rittirsch,et al. Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.
[20] S. Sell,et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. , 2013, Blood.
[21] Ralph Weissleder,et al. Arthritis critically dependent on innate immune system players. , 2002, Immunity.
[22] D. Fry. Article Commentary: Sepsis, Systemic Inflammatory Response, and Multiple Organ Dysfunction: The Mystery Continues , 2012, The American surgeon.
[23] Kutty Selva Nandakumar,et al. Inhibiting the C5-C5a receptor axis. , 2011, Molecular immunology.
[24] K. Langa,et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. , 2010, JAMA.
[25] P. Monk,et al. International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors , 2013 .
[26] K. Messlinger,et al. Inhibition of stimulated meningeal blood flow by a calcitonin gene‐related peptide binding mirror‐image RNA oligonucleotide , 2006, British journal of pharmacology.
[27] P. Monk,et al. Correction to “International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors” , 2014, Pharmacological Reviews.
[28] Anna J. Strachan,et al. Inhibition of immune‐complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist , 2002, British journal of pharmacology.
[29] S. Klußmann,et al. Identification and characterisation of C5a-inhibiting biostable aptamers , 2010 .
[30] P. Ward,et al. Protective effects of C5a blockade in sepsis , 1999, Nature Medicine.
[31] J. V. Sarma,et al. Complement-Induced Impairment of Innate Immunity During Sepsis1 , 2002, The Journal of Immunology.
[32] J. Solomkin,et al. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. , 1981, Surgery.
[33] P. Ward,et al. Manipulation of the Complement System for Benefit in Sepsis , 2012, Critical care research and practice.
[34] H. Pavenstädt,et al. The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis , 2011, Critical care.
[35] John D Lambris,et al. C5a and TNF-α Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome1 , 2008, The Journal of Immunology.
[36] S. Klußmann,et al. Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First‐in‐Class Mirror‐Image Oligonucleotide Inhibitor of CXCL12 , 2013, Clinical pharmacology and therapeutics.
[37] R. Boisgard,et al. In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[38] G. Kumar,et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). , 2011, Chest.
[39] Hongjun Bai,et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. , 2013, Immunobiology.
[40] M. J. Evans,et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. , 1995, Molecular immunology.
[41] J. V. Sarma,et al. Functions of the complement components C3 and C5 during sepsis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] F. Tacke,et al. High C5a levels are associated with increased mortality in sepsis patients--no enhancing effect by actin-free Gc-globulin. , 2008, Clinical biochemistry.
[43] J. Hamer,et al. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata* , 2007, Journal of Biological Chemistry.
[44] T. Luedde,et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury , 2011, Gut.
[45] S. Klußmann,et al. RNA Aptamers and Spiegelmers: Synthesis, Purification, and Post‐Synthetic PEG Conjugation , 2011, Current protocols in nucleic acid chemistry.
[46] R. Rieben,et al. Role of complement and perspectives for intervention in ischemia-reperfusion damage , 2012, Annals of medicine.
[47] P. Pronovost,et al. Long-term mortality and quality of life in sepsis: A systematic review* , 2010, Critical care medicine.
[48] S. Sell,et al. A Mixed Mirror-image DNA/RNA Aptamer Inhibits Glucagon and Acutely Improves Glucose Tolerance in Models of Type 1 and Type 2 Diabetes , 2013, The Journal of Biological Chemistry.
[49] S. Klußmann,et al. An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Schmidt,et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. , 2002, The Journal of clinical investigation.
[51] P. Ward,et al. Role of C5a in Multiorgan Failure During Sepsis1 , 2001, The Journal of Immunology.